Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.6M
Doctors Paid
583
Transactions
2,682
2024 Total
$21.2M
Payment Breakdown by Category
Research$38.8M (97.9%)
Consulting$342,321 (0.9%)
Food & Beverage$51,210 (0.1%)
Travel$29,303 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$38.8M
1,508 transactions
General
$850,838
1,170 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Juneko Grilley-Olson, M.d, M.D | Hematology & Oncology | Chapel Hill, NC | $5,220 | $0 |
| Gina D'amato, Md, MD | Internal Medicine | Atlanta, GA | $5,178 | $0 |
| Jaffer Ajani, M.d, M.D | Medical Oncology | Houston, TX | $5,109 | $0 |
| Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Cleveland, OH | $5,048 | $0 |
| David O'malley, M.d, M.D | Gynecologic Oncology | Hilliard, OH | $4,324 | $0 |
| Jonathan Trent, M.d., Ph. D, M.D., PH. D | Medical Oncology | Miami, FL | $4,241 | $0 |
| Vinod Ravi, Md, MD | Medical Oncology | Houston, TX | $4,215 | $0 |
| Richard Schilsky, Md, MD | Hematology & Oncology | Burr Ridge, IL | $4,042 | $0 |
| Dr. Krishnansu Tewari, M.d, M.D | Gynecologic Oncology | Orange, CA | $3,966 | $0 |
| Dr. Michael Rogawski, M.d, M.D | Neurology | Sacramento, CA | $3,763 | $0 |
| G Thomas Budd, Md, MD | Medical Oncology | Cleveland, OH | $3,655 | $0 |
| Dr. Jonathan Rosenberg, Md, MD | Internal Medicine | New York, NY | $3,600 | $0 |
| Dr. Eric Nadler, Md, MD | Medical Oncology | Dallas, TX | $3,500 | $0 |
| Neal Rosen, Md, MD | Medical Oncology | New York, NY | $3,500 | $0 |
| Olatunji Alese, M.d, M.D | Hematology & Oncology | Atlanta, GA | $3,415 | $0 |
| Dr. Sant Chawla, M.d, M.D | Specialist | Santa Monica, CA | $3,382 | $0 |
| Mihaela Druta, M.d, M.D | Medical Oncology | Tampa, FL | $3,330 | $0 |
| Dr. Breelyn Wilky, Md, MD | Internal Medicine | Aurora, CO | $3,270 | $0 |
| Dr. Mrinal Gounder, M.d, M.D | Internal Medicine | New York, NY | $3,215 | $0 |
| Bassel El-Rayes, Md, MD | Hematology | San Diego, CA | $3,199 | $0 |
| Dr. Ramez Eskander, M.d, M.D | Obstetrics & Gynecology | Encinitas, CA | $3,106 | $0 |
| Dr. Robert Coleman, Md, MD | Emergency Medicine | Bristol, TN | $3,106 | $0 |
| John Hays, M.d., Ph.d, M.D., PH.D | Medical Oncology | Columbus, OH | $3,106 | $0 |
| Alexander Olawaiye | Gynecologic Oncology | Pittsburgh, PA | $3,100 | $0 |
| David Liebner, Md, MD | Hematology & Oncology | Columbus, OH | $3,042 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.